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Abstract
Background—Breast cancer occurs rarely in men. To the best of our knowledge, there are no 
population-based estimates of the incidence of HER2-neu-positive breast cancer or of the 
distribution of breast cancer subtypes among male patients. We explored breast tumor subtype 
distribution by race/ethnicity among men in the large, ethnically diverse population of California.
Methods—We included male breast cancer patients diagnosed with invasive breast cancer 
between 2005-2009 with known ER, PR and HER2-neu status reported to the California Cancer 
Registry. Among the patients with hormone receptor (HR)-positive tumors, survival probabilities 
between groups were compared using log-rank tests.
Results—Six-hundred and six patients were included. Median age at diagnosis was 68 years. 
Four hundred and ninety four (81.5%) patients had HR+ tumors, defined as ER+ and/or PR+ and 
HER2-negative. Ninety (14.9%) had HER2-neu-positive, and 22 (3.6%) had triple receptor-
negative tumors (TN). Among HR+ patients, Non-Hispanic Blacks and Hispanics were more 
likely to have PR negative tumors compared to Non-Hispanic Whites. There was a borderline 
statistically significant difference in survival according to tumor subtype (p=0.088). Differences in 
survival according to race/ethnicity were seen among all patients (p=0.087) and among those with 
HR+ tumors (p=0.0170), with Non-Hispanic Blacks having poorer outcomes.
Conclusions—In this large, representative cohort of male breast cancer patients, the distribution 
of tumor subtypes was different from that reported for females and varied by race/ethnicity. Non-
Hispanic Blacks were more likely to have triple receptor-negative tumors and more likely to have 
ER+/PR- tumors than white men.
BACKGROUND
Male breast cancer is an uncommon disease, and it accounts for only 0.6-1% of all breast 
cancer cases 1. In 2011, it is estimated that a total of 2140 males will be diagnosed with 
breast cancer in the United States 2. The etiology of male breast cancer is unclear, but 
hormonal levels and testicular abnormalities play a role in the development of this disease. 
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BRCA2 mutations have been shown to confer a significant risk of breast cancer in men. 
Other recognized risk factors include radiation exposure, family history of breast cancer, 
Klinefelter syndrome and different benign breast conditions 3, 4.
Prior reports suggest that cancers of the male breast are more likely than female breast 
cancers to have a ductal histology and significantly more likely to express hormone 
receptors, even after adjustment for tumor stage, grade, and patient age 5, 6. Early reports 
had suggested equivalent or even higher rates of Her2-neu overexpression in male than 
female breast cancer 4, 7-9. However, those studies were small and were performed before 
improved standardization of assay methodology and may have overestimated Her2-neu 
overexpression 3, 10.
As knowledge about the biology of breast cancer improves, it has become clear that breast 
cancers should be classified according to tumor subtype. The categorization of breast 
cancers into hormone positive, Her2-neu positive and triple receptor-negative tumors has 
important implications in the prognosis and in the management of breast cancer patients. 
Among female patients with breast cancer there are strong racial/ethnic differences in the 
tumor subtype distribution 11. In this population-based study we explored the distribution of 
the different breast cancer tumor subtypes according to race/ethnicity among male breast 
cancer patients identified through the California Cancer Registry (CCR).
METHODS
Study Population and Variables
We used data from the California Cancer Registry (CCR), a population-based registry that 
collects data from all the cancer cases diagnosed in California since 1988. By state law all 
cancer cases are reported to the CCR from hospitals and any other facility providing care or 
therapy to cancer patients residing in California 12; it is estimated that case ascertainment is 
99% complete 13. Cancer patient information including demographic characteristics (age, 
race/ethnicity), tumor characteristics and treatment information were abstracted from the 
medical record by trained tumor registrars. The CCR collected data on estrogen receptor 
(ER) and progesterone receptor (PR) since 1990 and started collecting HER2-neu data since 
1999; however, for HER2-neu reporting, uptake was not immediate. Issues associated with 
collection and reporting of HER2-neu status have been previously described 14. Because 
HER2-neu was more likely to be present in the medical record and thereby reported to the 
CCR for patients diagnosed after 2005, we limited our assessment to cases diagnosed in this 
year or later.
For the present study, all male breast cancer (International Classification of Disease-
Oncology codes [ICD-O-3] C50.0-C50.9) patients diagnosed with a first primary invasive 
breast cancer between 2005 and 2009 were identified (n=829). Patients diagnosed on death 
certificate or autopsy only (n=4) and those with missing or invalid follow up data were 
excluded (n=1); additionally only patients with complete information on ER, PR and HER2-
neu status were included (resulting n=606). Patients excluded from our study for unknown 
receptor status did not differ significantly from those included with respect to age or race/
ethnicity. No differences were seen in the distribution according to stage (all p>0.05), 
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however patients excluded from the study had a higher proportion of unknown stage (p<.
001). In addition, patients diagnosed in 2005, were more likely to be excluded than patients 
who were diagnosed in subsequent years (p<0.020)
We used the American Joint Committee on Cancer (AJCC) staging system (6th edition). 
Tumor histology was classified as ductal (ICD-O-3 morphology code 8500, 8501, 8502, 
8503, 8504, 8507, 8708, 8523), lobular (ICD-O-3 morphology code 8520, 8521) and 
papillary/mixed/other (morphology code 8550, 8260, 8522, 8524). Breast cancer subtypes 
were defined as: Hormone receptor-positive (HR) (ER-positive and/or PR-positive and 
HER2-neu-negative), HER2-neu-positive (HER2-neu-positive, regardless or ER and PR) 
and triple -negative (TN) (HER2-neu-negative and ER-negative and PR-negative). Race/
ethnicity was categorized into four mutually exclusive groups: Non-Hispanic White, Non-
Hispanic Black, Hispanic and Asian/Pacific Islander (API)/other.
Data analysis
Descriptive statistics were used to evaluate the characteristics of the patient population. 
Differences between groups were assessed using chi square test and Fisher's exact test. For 
each patient, information on vital status was obtained from the CCR. The CCR regularly 
updates vital status information through hospital follow-up and linkages with state and 
national databases and agencies, such as the National Death Index, Social Security 
Administration, Centers for Medicaid and Medicare Services, Office of Statewide Health 
Planning and Development, CalVoter, Indian Health Service, National Change of Address, 
Department of Motor Vehicles, birth certificate linkages, and state vital statistics. Seventy-
four percent of our cases had confirmed vital status as of December 31st, 2010, and 88% had 
confirmed vital status within 3 months of that date. Survival time was measured in months 
since diagnosis. Kaplan-Meier analysis was used to calculate probability of survival. Cases 
were censored if they were alive as of December 31, 2010. The median follow-up time was 
33.7 months (range 2.7-71.9 months). Cases with complete follow-up did not differ 
significantly on age, race, stage, tumor subtype, year of diagnosis, or socioeconomic status 
from cases without current follow-up (chi square p>.05).
Survival analysis according to tumor subtype and race/ethnicity was performed, and 
differences between groups were compared using the log-rank test. A sub analysis of 
survival by race/ethnicity was also performed limited to patients with HR-positive tumors. A 
Cox proportional hazard analysis was performed, including race/ethnicity, stage and age in 
the model. Tumor subtype had a significant interaction with time and violated the 
proportional hazards assumption; therefore we stratified the final model by subtype. 
Statistical analyses were performed using SAS version 9.3 software (SAS institute Inc., 
Cary, NC, USA) and R (R Foundation for Statistical Computing, Vienna, Austria).
De-identified data from the CCR was used for all the analyses; however, in order to preserve 
confidentiality, in all the tables, cells with numbers < 5 were suppressed. The IRB of the 
Cancer Prevention Institute of California approved this analysis, while that of the University 
of Texas MD Anderson Cancer Center provided an exemption.
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A total of 829 male patients with primary invasive breast cancer were identified between 
2005 and 2009. Of them, 606 (73.2%) had available information on ER, PR and HER2 
status. Among the 606 patients included in this study, the median age at diagnosis was 68 
years old. The majority of the patients were Non-Hispanic White (71%, n=431), 7.4% 
(n=45) were Non-Hispanic Black, 11.1% (n=67) were Hispanic, and 10.4% (n=63) were 
API/other/unknown. Four hundred and ninety four (81.5%, 95%CI 78.4%-84.6%) of the 
patients had HR-positive tumors, ninety (14.9%, 95%CI 12.0%-17.7%) had HER2-positive 
and 22 (3.6%, 95%CI 2.1%-5.1%) had TN tumors. Table-1 shows patient characteristics 
according to tumor subtype. There was a statistically significant difference in the 
distribution of tumor subtype according to age (p=0.020) with younger patients having more 
HER2-positive disease. Among Non-Hispanic Whites, 82.8% (95%CI 79.3%-86.4%) of the 
patients had HR-positive tumors, 14.6% (95%CI 11.3%-18.0%) had HER2-positive and 
2.6%(95%CI 1.1%-4.0%) had TN breast cancer. In contrast, the distribution among Non-
Hispanic Blacks according to tumor subtype was 73.3% (95%CI 60.4%-86.3%); 17.8% 
(95%CI 6.6%-29.0%) and 8.9% (95%CI 0.6%-17.2%) and for Hispanics was 77.6% (95%CI 
67.6%-87.6%), 16.4% (95%CI 7.6-27.5%) and 6.0% (95%CI 0.3%-11.6%) for HR-positive, 
HER2-neu-positive and TN tumors, respectively.
HR-positive patients represented the most common breast cancer subtype in our patient 
population (n=494), so we evaluated ER and PR status separately. Table-2 shows the 
different combinations of ER and PR status among HR-positive patients according to race/
ethnicity. We observed that Hispanics and Non-Hispanic Blacks were more likely to have 
ER-positive and PR-negative tumors compared to Non-Hispanic Whites (17.3% (95%CI 
7.0%-27.6%), 15.2% and 4.5% (95% CI 2.3-6.6%), respectively p<0.001).
Although we had small numbers of cases and deaths to study (total number of events= 117), 
we next evaluated whether overall survival varied by tumor subtype. Figure-1 shows a 
Kaplan-Meier curve that suggests worse survival among patients with TN tumors, although 
the log-rank-test was borderline significant (p=0.088). Figure-2 shows significant 
differences in survival by race/ethnicity among all the participants (n=606) with Non-
Hispanic Blacks being the group with the worst outcomes (p=0.008). The observed 
differences could be explained by the different distribution of tumor subtype according to 
race. For that reason, we aimed to explore the survival of patients according to each tumor 
subtype by race/ethnicity. Unfortunately, given the small number of patients we could not 
examine separate influences for HER2-neu-positive and TN tumors. In Figure-3 we show 
the Kaplan Meier curve according to race/ethnicity for patients with HR-positive tumors 
(n=494), demonstrating significant survival differences according to race/ethnicity 
(p=0.017). Among this group of patients, Non-Hispanic Blacks had the worst survival.
After adjusting for subtype, stage and age and using Non-Hispanic Whites as a reference 
category, we observed no significant differences in survival according to race/ethnicity 
(Hispanics HR: 0.78 95% CI 0.38-1.58; Non-Hispanic Blacks HR: 1.32; 95% CI 0.75-2.33 
and API/other HR: 0.631 95% CI 0.27-1.46), suggesting that the effect of race/ethnicity on 
survival was attenuated by stage.
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To the best of our knowledge, this is the first and largest population-based study evaluating 
tumor subtype distributions in male breast cancer patients. The majority of the male breast 
cancer patients in our study (81.5%) had HR-positive tumors. We observed that a clinically 
significant proportion of patients have HER2-positive tumors (14.9%), and a low proportion 
have TN tumors (3.6%). In a large study including more than 60,000 females using data 
from the CCR, 63.8% of the patients had HR-positive, 22.8% had HER2-neu-positive and 
13.4% had TN tumors 15, suggesting that male patients have lower rates of HER-2 positive 
and triple negative tumors than their female counterparts. It has been well described that 
male patients with breast cancer are more likely than their female counterparts to have HR-
positive tumors 3, 5, 6, 16. It is estimated that the incidence of ER and PR– positive tumors is 
82% and 75% among males and 69% and 52% among females4. The data on HER2 
overexpression is inconsistent in the literature; older studies reported similar or higher rates 
of HER2-neu overexpression between males and females 3, 4, 7-9, with pooled data 
suggesting a 35% rate of overexpression in males. In a study published by Bloom et al 10, 58 
male breast cancer specimens were evaluated. HER2-neu overexpression was identified in 
only one case (1.7%) and amplification was not seen. Importantly, this study included a 
subset of patients (n=26) that had been considered Her2-neu overexpressed in a previous 
report 9 and none of them was found to have overexpression at the time of the reevaluation. 
The small number of patients and the differences in techniques used for HER2-neu 
determination may underlie the overestimation of the previously reported rates of HER2-neu 
expression among male breast cancer patients 3. In our study, 14.9% of the patients were 
categorized as HER2-neu-positive. Our results are similar to the 17% rate that Muir and 
colleagues reported 16 and to the 15% rate of HER2 amplification that the European Institute 
of Oncology described 17; however, these are small studies including only 59 and 27 
patients, respectively. The rates of TN tumors in male breast cancer patients are not clearly 
described and the frequency remains largely unknown. We observed a 3.8% rate of TN 
tumors, a rate that is substantially lower than what has been reported in female patients. A 
recent study by Arslan et al described a 5.9% rate of TN patients in a Turkish population of 
male breast cancer patients (n=118) 18.
Among female patients with breast cancer, the categorization of breast tumors into different 
subtypes has important prognostic implications. After adjusting for clinical and demographic 
characteristics, patients with HR-positive tumors have better outcomes compared with 
patients with HER2-neu-positive and TN tumors. It is not clear if breast cancer subtypes are 
associated with the same prognostic factors among males. A Mayo Clinic study reported no 
association between HER2-neu overexpression and survival in univariate analysis among a 
cohort of 76 male breast cancer patients 8. More recently Arslan et al (n=118), observed a 
non statistically significant difference in 5-year overall survival among male patients with 
HER2-neu-positive compared to patients with HER2-neu-normal tumors (85 months vs 144 
months, p=0.30) 18. In our study we observed that patients with TN tumors tend to have 
worse survival compared to patients with HR positive or HER2-neu-positive tumors; this 
difference had borderline statistical significance (p=0.088). It is important to point out that 
our patient population included patients that were treated after the approval of trastuzumab-
Chavez-MacGregor et al. Page 5













based chemotherapy; therefore, is possible that the patients with HER2-neu-positive tumors 
received this treatment, likely improving their outcomes when compared with patients with 
TN tumors. Our results suggest that among male breast cancer patients, tumor subtype does 
hold prognostic significance. However, the small number of patients with TN and HER2-
neu-positive tumors, the short follow-up, and the fact that we could not perform any 
multivariable analysis to adjust for clinically relevant characteristics, warrant careful 
interpretation.
Among female patients with breast cancer, clear racial/ethnic differences exist in the 
distribution of tumor subtypes 11, 15. Non-Hispanic Blacks have higher rates of TN or basal-
like tumors and are less likely to have tumors that are ER-positive and PR-positive. In our 
study, a similar pattern seems to be present among male patients with breast cancer, 
although this difference was not statistically significant (p=0.227). The high frequency of 
tumors associated with poor prognosis is one theory promulgated to explain, at least in part, 
the poor outcomes seen in Non-Hispanic Black female patients compared to other ethnic/
racial groups. Among female breast cancer patients with HR-positive tumors, worse 
outcomes have been reported in Non-Hispanic Blacks compared to Non-Hispanic 
Whites 19, 20. In our study, among male breast cancer patients with HR-positive tumors 
(n=494), Non-Hispanic Blacks had worse survival compared to the other racial/ethnic 
groups (p=0.017).
When we explored separately the distribution PR status among patients with ER-positive 
tumors, significant differences were observed (p<0.001). Only 4.25% of Non-Hispanic 
Whites had PR-negative tumors, compared with 15.26% and 17.3% among Non-Hispanic 
Blacks and Hispanics, respectively. In a large study from the CCR evaluating 1796 male 
patients with breast cancer from 1988-2000 21, a similar observation was described. Among 
patients with known PR status (n=862), Non-Hispanic Whites, Hispanic and Asians had PR-
positive tumors (81%, 90% and 79.6%, respectively) more frequently than Non-Hispanic 
Blacks (64.1%). We consider this to be an important observation that can help understand 
the poor outcomes seen among Non-Hispanic Blacks. In female patients, ER+/PR- tumors 
have been associated with tamoxifen resistance and a more aggressive phenotype compared 
to ER+/PR+ tumors22-24. Female patients older than 60 years old with ER+/PR- tumors have 
worse outcomes compared with patients in the same age category but with ER+/PR+ 
tumors25.
In an exploratory analysis we aimed to eliminate the potential effect of ER+/PR-tumors by 
limiting the survival analysis according to race/ethnicity to patients with ER+/PR+ tumors 
exclusively. Non-Hispanic Blacks had worse survival (p=0.023). Unfortunately, this does 
not help explain the clinical behavior of Hispanic patients who despite also having high rates 
of ER+/PR- tumors have better survival compared to Non-Hispanic Blacks.
Our study had several important limitations. Despite including one of the largest and most 
diverse populations of male breast cancer patients in the U.S., the overall number of patients 
with HER2-positive and TN tumors was small. Also, our necessarily short follow-up and the 
small number of events limited our statistical analyses and we were only able to build a 
multivariate model to evaluate outcomes adjusting for a limited number of baseline 
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characteristics. Limitations inherent to population-based studies such as potential errors in 
reporting or differences in laboratory techniques to assign the tumor marker status cannot be 
quantified. The status of the biomarkers (ER, PR and HER2) was obtained from the CCR 
but it was originated in different local pathology laboratories, therefore no information on 
quality control is available and no central biomarker review was possible. Also, the 
categories that we used in this manuscript to categorize tumor subtypes are derived 
exclusively from data on ER, PR and HER2; no information was available on molecular 
profiles. Our cohort included only patients with known ER, PR and HER2 status. Patients 
included in the study had similar characteristics than those excluded, however those 
excluded were more likely to be diagnosed in 2005. A sensitivity analysis (data not shown) 
including only patients diagnosed from 2006-2009 (n=519) show similar results.
To our knowledge, this is the first population-based study reporting tumor subtypes among 
male breast cancer patients. The majority of the patients had HR-positive tumors; however, 
HER2-neu overexpression was seen in 14.9% of the patients and 3.6% of the patients had 
TN tumors; this observation has potential prognostic and treatment implications. Among 
male patients with breast cancer, differences in tumor subtype exist among different racial/
ethnic groups. Non-Hispanic Blacks were numerically more likely to have triple receptor-
negative tumors and more likely to have ER+/PR- tumors than Non-Hispanic Black patients.
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Kaplan-Meier curves illustrate the probability of survival among men with breast cancer 
according to tumor subtype (n = 606). Hormone receptor-positive (HR+), human epidermal 
growth factor receptor 2 (HER2) and triple negative.
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Kaplan-Meier curves illustrate the probably of survival among men with breast cancer 
according to race/ethnicity. API indicates Asian/Pacific Islander (n = 606).
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Kaplan-Meier curves illustrate the probably of survival among men with breast cancer 
according to race/ethnicity for those with (hormone receptor)-positive tumors (n = 494). API 
indicates Asian/Pacific Islander.
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Table 1
Patient characteristics according to tumor subtype
Tumor Subtype
All HR+ Her 2+ Triple negative
N N Row % N Row % N Row %
606 494 81.5% 90 14.9% 22 3.6%
Age at diagnosis p=0.0204
<50 60 40 66.7% 17 28.3%
<5 
* 5.0%
50-69 268 223 83.2% 38 14.2% 7 2.6%
70+ 278 231 83.1% 35 12.6% 12 4.3%
Race p=0.2274
Non-Hispanic White 431 357 82.8% 63 14.6% 11 2.6%
Non-Hispanic Black 45 33 73.3% 8 17.8%
<5 
* 8.9%
Hispanic 67 52 77.6% 11 16.4%
<5 
* 6.0%




2005 87 66 75.9% 17 19.5%
<5 
* 4.6%
2006 133 102 76.7% 22 16.5% 9 6.8%
2007 114 94 82.5% 16 14.0%
<5 
* 3.5%
2008 133 110 82.7% 20 15.0%
<5 
* 2.3%




1 70 57 81.4% 8 11.4% 5 7.1%
2 97 77 79.4% 19 19.6%
<5 
* 1.0%
3 125 101 80.8% 19 15.2% 5 4.0%
4 119 95 79.8% 19 16.0% 5 4.2%
5 195 164 84.1% 25 12.8% 6 3.1%
Tumor histology p=0.6915
ductal 513 419 81.7% 77 15.0% 17 3.3%
lobular 11 9 81.8%
<5 
* 18.2% 0 0
papillary/mixed/other 82 66 80.5% 11 13.4% 5 6.1%
Grade p<.0001
Grade I 83 71 85.5% 9 10.8%
<5 
* 3.6%
Grade II 315 271 86.0% 42 13.3%
<5 
* 0.6%
Grade III/ IV 183 133 72.7% 34 18.6% 16 8.7%
Unknown 25 19 76.0% 5 20.0%
<5 
* 4.0%
Stage at diagnosis p=0.2277
I 195 167 85.6% 21 10.8% 7 3.6%
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Tumor Subtype
All HR+ Her 2+ Triple negative
N N Row % N Row % N Row %
606 494 81.5% 90 14.9% 22 3.6%
II 248 203 81.9% 36 14.5% 9 3.6%
III 101 80 79.2% 18 17.8%
<5 
* 3.0%




No surgery 32 22 68.8% 8 25.0%
<5 
* 6.3%
Mastectomy 495 413 83.4% 73 14.7% 9 1.8%
Breast conservation 79 59 74.7% 9 11.4% 11 13.9%
Radiation therapy p=0.6657
no/unknown 441 356 80.7% 69 15.6% 16 3.6%
yes 165 138 83.6% 21 12.7% 6 3.6%
Vital status as of Dec. 31, 2010 p=0.0770
Dead 117 89 76.1% 20 17.1% 8 6.8%
Alive 489 405 82.8% 70 14.3% 14 2.9%
*
Cell counts <5 have been suppressed to protect patient confidentiality
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Table 2
Tumor receptor status combinations according to race for HR+ and Her2- patients
Race
All Non-Hispanic White Non-Hispanic Black Hispanic API/other/unknown
N N Column % N Column % N Column % N Column %
HR status
ER+PR+ 456 336 (94.1%) 27 (81.8%) 42 (80.8%) 51 (98.1%)
ER+PR- 31 16 (4.5%) 5 (15.2%) 9 (17.3%)
<5 
* (1.9%)




* (1.9%) 0 0
All 494 357 (100.0%) 33 (100.0%) 52 (100.0%) 52 (100.0%)
P=<0.001
*
Cell counts <5 have been suppressed to protect patient confidentiality
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